Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINKER-MM3: linvoseltamab versus EPd in relapsed/refractory multiple myeloma
NL-OMON59853Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-free survival per IRC in CD38 antibody-exposed participants. Started May 2024; status: active, not recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59853.